Ignite Creation Date:
2025-12-24 @ 1:58 PM
Ignite Modification Date:
2026-01-01 @ 12:31 AM
Study NCT ID:
NCT06644495
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-10-16
First Post:
2024-10-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Post-Market Surveillance Study of ALK-Positive Advanced NSCLC Participants Treated With Iruplinalkib
Sponsor:
Qilu Pharmaceutical Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-12
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-04-30
Completion Date Type:
ESTIMATED
First Submit Date:
2024-10-11
First Submit QC Date:
None
Study First Post Date:
2024-10-16
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-14
Last Update Post Date:
2024-10-16
Last Update Post Date Type:
ACTUAL